natgillin/translations-raw huggingface dataset:
R and R' represent, the same or different from each other, a group of formula -NHR1 or -NR2R3, wherein each R1, R2 and R3 is, independently from each other, a straight or branched C1-C6 alkyl group which is optionally substituted by one or more groups selected from hydroxyl (-OH), C1-C5 alkoxy or hydroxyalkoxy groups. 
R i R' predstavljaju, istu ili međusobno različitu, skupinu s formulom -NHR1 ili -NR2R3, pri čemu svaki R1, R2 i R3 je, međusobno neovisno, ravnolančana ili razgranata C1-C6 alkil skupina koja je proizvoljno supstituirana s jednom ili više skupina odabranih iz skupine koju čine hidroksil (-OH), C1-C5 alkoksi ili hidroksialkoksi skupine.
The process of claim 7 comprising: obtaining an aqueous solution of 3,5-di-substituted phenol substrate of formula 1, or of a salt thereof, and adding I2 and HIO3 to said aqueous solution. 
Postupak prema zahtjevu 6 naznačen time da sadrži: dobivanje vodene otopine supstrata 3,5-disupstituiranog fenola s formulom 1, ili njegove soli, te dodavanje I2 i HIO3 u navedenu vodenu otopinu.
The process of claims 7-8 comprising adding solid I2 to said aqueous solution of 3,5-di-substituted phenol substrate heated to a temperature comprised from 20 to 70°C and then adding iodic acid. 
Postupak prema zahtjevima 7-8 naznačen time da sadrži dodavanje krutog I2 u navedenu vodenu otopinu supstrata 3,5-disupstituiranog fenola zagrijanu na temperaturu u rasponu od 20 do 70°C i zatim dodavanje jodne kiseline.
The process of claim 10 wherein the iodic acid is added when the reaction mixture has a pH comprised from 5 to 6. 
Postupak prema zahtjevu 9 naznačen time da se jodna kiselina dodaje kada reakcijska smjesa ima pH u rasponu od 5 do 6.
and R5 are, the same or different from each other, hydrogen or a straight or branched C1-C6 alkyl group, optionally substituted by one or more hydroxyl or C1-C6 alkoxy groups, comprising: 
i R5 su, isti ili međusobno različiti, vodik ili ravnolančana ili razgranata C1-C6 alkil skupina, proizvoljno supstituirana s jednom ili više hidroksil ili C1-C6 alkoksi skupina, koji sadrži:
preparing a triiodophenol compound of formula 2 according to the process of anyone of claims 1-12; said process further comprising: 
pripremu spoja trijodofenola s formulom 2 prema postupku iz bilo kojeg zahtjeva 1-11; te navedeni postupak nadalje sadrži:
reacting said compound of formula 2, either as such or comprising the phenolic OH group in the form of a salt with an alkali metal, with a compound of formula 3 R4HN(C=O)CH(R5)Z 3 wherein R4 and R5 are, the same or different from each other, as defined above, and Z is a halogen atom selected from chlorine or bromine, or a leaving group selected from methanesulfonyloxy, benzenesulfonyloxy, nitrobenzenesulfonyloxy, toluensulfonyloxy, to obtain a compound of formula 4 wherein R, R', R4 and R5 have the above reported meanings; and 
reakciju navedenog spoja formule 2, bilo kao takvog ili koji sadrži fenolnu OH skupinu u obliku soli s alkalnim metalom, sa spojem formule 3 HN(C=O)CH(R5)Z 3 pri čemu R4 i R5 su, isti ili međusobno različiti, kako je gore definirano, i Z je atom halogena odabran od klora ili broma, ili izlazna skupina odabrana između metansulfoniloksi, benzensulfoniloksi, nitrobenzensulfoniloksi, toluensulfoniloksi, da se dobije spoj s formulom 4 [image] pri čemu R, R', R4 i R5 imaju gore navedena značenja; i
subjecting said compound of formula 4 to Smiles's rearrangement in the presence of a base to obtain the compound of formula 5. 
podvrgavanje navedenog spoja formule 4 Smiles-ovom preuređenju u prisutnosti baze, kako bi se dobio spoj formule 5.
The process of claim 12 wherein both R and R' are a -NH-CH(CH2OH)2 group, R4 is hydrogen and R5 is methyl group. 
Postupak prema zahtjevu 12 naznačen time da oba R i R' su -NH-CH(CH2OH)2 skupina, R4 je vodik i R5 je metil skupina.
System for transmitting digital signals comprising a QAM modulator, characterized in that it is adapted to implement the method according to any one of claims 1 to 3. 
Sustav za prijenos digitalnih signala koji sadrže modulator QAM, naznačen time, da je prilagođen za primjenu postupka u skladu s bilo kojim od patentnih zahtjeva 1 do 2.
System for receiving digital signals comprising a QAM demodulator, characterized in that it is adapted to implement the method according to any one of claims 6 to 8. 
Sustav za prijam digitalnih signala koji sadrži QAM demodulator, naznačen time, da je prilagođen za primjenu postupka u skladu s bilo kojim od patentnih zahtjeva 5 do 6.
The proNGF mutant according to claim 1, wherein the mutant is obtained by recombinant expression in prokaryotic cells, preferably by recombinant expression in E. coli. 
proNGF mutant prema zahtjevu 1, naznačen time da se mutant dobiva pomoću rekombinantne ekspresije u prokariotskim stanicama, poželjno pomoću rekombinantne ekspresije u E. coli.
transferring the proNGF mutant into a refolding solution where the denatured proNGF assumes a biologically active conformation, 
prenošenje proNGF mutanta u otopinu za ponovno preslagivanje gdje denaturirani proNGF podrazumijeva biološki aktivnu konformaciju,
purifying the refolded proNGF mutant. 
pročišćavanje ponovno presloženog proNGF mutanta,
wherein the denaturing solution comprises a solution containing (i) a chaotropic substance, (ii) a chelator, (iii) a buffer, and (iv) a reducing agent, preferably, wherein the denaturing solution comprises 
naznačen time da otopina za denaturaciju sadrži otopinu koja sadrži (i) kaotropnu tvar, (ii) kelator, (iii) pufer, te (iv) redukcijsko sredstvo, poželjno, pri čemu otopina za denaturaciju sadrži
pH 7.0 -10.0, and more preferably comprises 
pH 7.0 -10.0, te poželjnije sadrži
pH 8.0 - pH 11.0, preferably, wherein the refolding solution comprises 
pH 8.0 - pH 11.0, poželjno, pri čemu otopina za ponovno preslagivanje sadrži
The method according to claims 4 or 5 wherein the refolding is carried out as a pulse renaturation, preferably, wherein in relation to the final refolding volume during pulse renaturation, the concentration of Guanidinium HCl does not exceed 0.3 M and the protein concentration per pulse should not exceed 50 µg/ml. 
Postupak prema zahtjevima 4 ili 5 naznačen time da se preslagivanje provodi kao impulsna renaturacija, poželjno, pri čemu u odnosu na konačni volumen ponovnog preslagivanja tijekom impulsne renaturacije, koncentracija Gvanidinij HCl ne prelazi 0.3 M i koncentracija proteina po impulsu ne smije prelaziti 50 µg/ml.
The method according to claims 4-7, wherein the pro-form of the proNGF mutant is cleaved by a protease, preferably by a serine protease, more preferably by trypsin. 
Postupak prema zahtjevima 4-7, naznačen time da se pro-oblik proNGF mutanta cijepa djelovanjem proteaze, poželjno djelovanjem serin proteaze, poželjnije djelovanjem tripsina.
Ra, Rb, Rc independently of one another denote C1-4-alkyl, phenyl or phenyl-C1-3-alkyl, while the alkyl groups may be mono- or polysubstituted by halogen; 
Ra, Rb, Rc međusobno neovisno označavaju C1-4-alkil, fenil ili fenil-C1-3-alkil, dok alkil-skupine mogu biti mono- ili polisupstituirane s halogenom;
while the phenyl groups mentioned in the definition of the above groups may be mono- or polysubstituted with L1; 
dok fenil-skupine koju su spomenute u definiciji gornjih skupina, mogu biti mono- ili polisupstituirane s L1;
comprising the steps (S2), (S3) and (S4): 
pri čemu postupak obuhvaća korake (S2), (S3) i (S4):
The process according to the claim 3 wherein at the beginning of, during or at the end of the step (S1) and/or at the beginning or during the step (S2) lithium bromide and/or lithium chloride is added to the reaction mixture whereby the molar ratio of the C3-4-alkyl-magnesium chloride or bromide to the lithium bromide and/or lithium chloride is in the range from 1: 10 to 10: 1, preferably 1: 1. 
Postupak prema zahtjevu 3, naznačen time, da na početku, za vrijeme njega ili na završetku koraka (S1) i/ili na početku ili za vrijeme koraka (S2), dodaje se litijev bromid i/ili litijev klorid u reakcijsku smjesu pri čemu je molarni omjer od C3-4-alkil-magnezijevog klorida ili bromida prema litijevom bromidu i/ili litijevom kloridu, u rasponu od 1: 10 do 10: 1, poželjno je 1:1.
The process according to the claim 2, 3 or 4 wherein the amount of the magnesium, lithium, a magnesium Grignard reagent or a lithium organic compound relative to the compound of the formula V is in the range from 0.5 to 2 mol, preferably equimolar. 
Postupak prema zahtjevu 2, 3 ili 4, naznačen time, da je količina magnezija, litija, magnezijevog reagensa Grignard ili litijevog organskog spoja, u odnosu na spoj formule V, u rasponu od 0,5 do 2 mola, poželjno je ekvimolama.
The process according to the claim 1, 2, 3, 4 or 5 wherein the solvents are selected from the group consisting of tetrahydrofuran, 2-methyltetrahydrofuran, tert. -butyl-methylether, diethylether, heptane, toluene, benzene, dioxane, methylcyclohexane, hexane, dimethyl sulfoxide, dichloromethane and chloroform, preferably selected from tetrahydrofuran and 2-methyltetrahydrofuran. 
Postupak prema zahtjevu 1, 2, 3, 4 ili 5, naznačen time, da su otapala odabrana iz skupine koju čine tetrahidrofuran, 2-metiltetrahidrofuran, tert-butil-metileter, dietileter, heptan, toluen, benzen, dioksan, metilcikloheksan, heksan, dimetil-sulfoksid, diklorometan i kloroform, a poželjno su odabrana od tetrahidrofurana i 2-metiltetrahidrofurana.
The process according to one or more of the claim 1 to 7 wherein the amount of the gluconolactone relative to the organometallic compound of the formula VI is in the range from 0.8 to 3 mol, preferably 1 to 2 mol, more preferably 1.06 mol. 
Postupak prema jednom ili više od zahtjeva 1 do 7, naznačen time, da je količina glukonolaktona u odnosu na organometalni spoj formule VI, u rasponu od 0,8 do 3 mola, poželjno od 1 do 2 mola, još bolje je to 1,06 mola.
The process according to one or more of the claims 1 to 11 wherein the organic phase of the reaction mixture in the step (S3) comprises 2-methyltetrahydrofurane in an amount in the range from 2 to 60 weight-%, preferably from 10 weight-% to 40 weight-%, more preferably from 15 to 35 weight-% relative to the total amount of the organic phase of the reaction mixture. 
Postupak prema jednom ili više od zahtjeva 1 do 11, naznačen time, da organska faza od reakcijske smjese u koraku (S3), sadrži 2-metiltetrahidrofuran u količini u rasponu od 2 do 60 masenih %, poželjno od 10 masenih % do 40 masenih %, još bolje od 15 do 35 masenih %, u odnosu na ukupnu količinu organske faze od reakcijske smjese.
The process according to one or more of the claims 1 to 15 wherein in the step (S5) the obtained adduct is reacted with an alcohol R'-OH, wherein the alcohol R'-OH is selected from the group consisting of methanol, ethanol, 1-propanol, 2-propanol, n-butanol, tert -butanol or mixtures thereof, preferably methanol. 
Postupak prema jednom ili više od zahtjeva 1 do 15, naznačen time, da u koraku (S5) dobiveni dodatak reagira s alkoholom R'-OH, pri čemu je alkohol R'-OH odabran iz skupine koju čine metanol, etanol, 1-propanol, 2-propanol, n-butanol, tert-butanol ili njihove smjese, poželjno metanol.
The process according to one or more of the claims 1 to 16 wherein in the step (S5) with the addition of the one or more acids a pH is to be obtained in a pH range from 0 to 7, preferably from 0 to 4, more preferably from 1 to 2. 
Postupak prema jednom ili više od zahtjeva 1 do 16, naznačen time, da u koraku (S5) s dodavanjem jedne ili više kiselina, treba se dobiti pH-vrijednost koja je u rasponu od 0 do 7, poželjno od 0 do 4, najbolje od 1 do 2.
The process according to one or more of the claims 1 to 17 wherein in the step (S5) the one or more acids are selected from the group consisting of hydrochloric acid, sulphuric acid, nitric acid, acetic acid, trifluoroacetic acid, citric acid, tartaric acid, oxalic acid and succinic acid, preferably hydrochloric acid. 
Postupak prema jednom ili više od zahtjeva 1 do 17, naznačen time, da u koraku (S5) jedna ili više kiselina je odabrana iz skupine koju čine klorovodična kiselina, sumporna kiselina, dušična kiselina, octena kiselina, trifluorooctena kiselina, limunska kiselina, vinska kiselina, oksalna kiselina i sukcinska kiselina, poželjno je to klorovodična kiselina.
Use of the process for preparing a glucopyranosyl-substituted benzyl-benzene derivative of general formula III, wherein 
Uporaba postupka za proizvodnju derivata benzil-benzena supstituiranog glukopiranozilom, opće formule III:
(S6) reacting the glucopyranosyl-substituted benzyl-benzene derivative of general formula III with a reducing agent. 
(S6) reakcija derivata benzil-benzena supstituiranog glukopiranozilom, opće formule III, sa sredstvom za redukciju.
A compound according to claim 1, wherein R1 is selected from the group consisting of H, 
Spoj prema zahtjevu 1, naznačen time, da R1 je odabran iz skupine koju čine:
A pharmaceutical composition according to claim 15, wherein it is useful for the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior. 
Farmaceutski sastav prema zahtjevu 15, naznačen time, da je koristan u prevenciji ili liječenju dismenoreje, muške i ženske seksualne disfunkcije, hipertenzije, kroničnog zatajenja srca, nepravilne sekrecije vazopresina, ciroze jetre, nefrotičkog sindroma, anksioznosti, depresivnih poremećaja, opsesivno kompulzivnog poremećaja, dijapazona autističkih poremećaja, shizofrenije i agresivnog ponašanja.
from 2% to 6% by weight hydroxypropyl methacrylate based on the weight of the nail coating composition; from 0.1 % to 1% by weight of a photoinitiator based on the weight of the nail coating composition; and 
od 2% do 6% hidroksipropil metakrilata; od 0,1% do 1% fotoinicijatora; i od 25 do 40% boje za lakove za nokte, pri čemu postoci označavaju težinske postotke izražene u odnosu na ukupnu težinu pripravaka.
A radiation curable gel nail coating composition according to claim 5, wherein the solvent is selected from isopropyl alcohol, ethanol, diacetone alcohol, ethyl acetate, butyl acetate, amyl acetate, acetone, or a mixture thereof. 
Pripravak u vidu gel-laka za nokte za čije sušenje se korisiti zračenje prema patentnom zahtjevu 5, naznačen time, što je otapalo izabrano iz grupe koju čine izopropil alkohol, etanol, diaceton alkohol, etil acetat, butil acetat, amil acetat, aceton ili njihove smjese.
A kit according to claim 13, wherein the bottle comprises clear glass coated with a finish to substantially exclude UV light transmission through the glass. 
Komercijalni komplet prema patentnom zahtjevu 13, naznačen time, što je bočica od prozirnog stakla i obložena folijom koja značajno sprječava prolaz UV svjetlosti kroz staklo.
A kit according to claim 13, further comprising a brush for applying the radiation curable gel nail coating composition. 
Komercijalni komplet prema patentnom zahtjevu 13, koji dalje sadrži četkicu za nanošenje pripravaka u vidu gel-laka za nokte za čije sušenje se korisiti zračenje.
from 3% to 6% by weight hydroxypropyl methacrylate based on the weight of the nail coating composition from 0.1% to 0.4% by weight of a photoinitiator based on the weight of the nail coating composition; and 
od 3% do 6% hidroksietil metakrilata; od 3% do 6% hidroksipropil metakrilata; od 0,1% do 0,4% fotoinicijatora; i pigmentirani lak za nokte, pri čemu postoci označavaju težinske postotke izražene u odnosu na ukupnu težinu pripravaka.
is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; 
je supstituirani ili nesupstituirani aril ili supstituirani ili nesupstituirani heteroaril;
The compound of any one of claims 1 to 7, wherein G2 is selected from the group below: wherein m is 1 and R3 is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino. 
Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time da je G2 izabran iz skupine ispod: [image] [image] pri čemu m je 1 i R3 je izabran iz skupine koju čine hidroksi, hidroksimetil, amino, acilamino, acetilamino i metilamino.
A drug delivery device (50) comprising: 
Uređaj za primjenu lijeka (50) koji se sastoji od:
a disposable housing (52) having an interior surface (80) defining an interior space (82), and an exterior surface (84); 
jednokratnog kućišta (52) s unutarnjom površinom (80) koja definira unutarnji prostor (82) i vanjskom površinom (84);
optionally wherein the controller (60) determines that at least a 24-hour period has elapsed after actuation of an input device (184). 
pri čemu opcionalno regulator (60) određuje da je proteklo najmanje 24 sata nakon aktivacije ulaznog uređaja (184).
optionally wherein the controller (60) is configured to actuate the reservoir (152) to deliver the volume of the drug to the patient as a single bolus in less than six seconds. 
pri čemu je regulator (60) opcionalno konfiguriran da aktivira spremnik (152) kako bi bolesniku primijenio volumen lijeka u obliku jednog bolusa za manje od šest sekundi.
The delivery device according to any one of the preceding claims, further comprising an adhesive adapted to releasably secure the housing (52) to skin during a single application, the adhesive disposed on a portion of the exterior surface (84) and covered with a removable, disposable sheet (104) prior to application of the housing (52) to the skin of a patient. 
Uređaj za primjenu prema bilo kojem od prethodnih zahtjeva, koji se dalje sastoji od adheziva prilagođenog da odvojivo pričvrsti kućište (52) za kožu prilikom jedne primjene, pri čemu se adheziv nalazi na dijelu vanjske površine (84) i prekriven je izmjenjivim, jednokratnim slojem (104) prije stavljanja kućišta (52) na kožu bolesnika.
The building panel according to claim 1 wherein the gas- impermeable divider (7) is comprised of float glass. 
Građevinski panel prema zahtjevu 1, naznačen time da se plinski-nepropusna pregrada (7) sastoji od float stakla.
The building panel according to claim 1 wherein the outer (2) and inner (1) plates are comprised of standard float glass. 
Građevinski panel prema zahtjevu 1, naznačen time da se vanjske (2) i unutarnje (1) ploče sastoje od standardnog float stakla.
The building panel according to claim 1 wherein the gas- impermeable divider (7) is comprised of tempered float glass of thickness 2 mm to 6 mm preferably approximately 4 mm. 
Građevinski panel prema zahtjevu 1, naznačen time što se plinski-nepropusna pregrada (7) sastoji od kaljenog stakla debljine 2 mm do 6 mm poželjno oko 4 mm.
The building panel according to claim 3 wherein the outer (2) and inner (1) plates are comprised of glass with thickness at least 6 mm. 
Građevinski panel prema zahtjevu 3, naznačen time što se vanjske (2) i unutarnje (1) ploče sastoje od stakla debljine najmanje 6 mm.
The building panel according to claim 1 wherein the openings (6) are holes drilled into the spacer (8). 
Građevinski panel prema zahtjevu 1, naznačen time da su otvori (6) rupe bušene u držaču razmaka (8).
is hydrogen or C1-C4 alkyl optionally substituted with hydroxy; and 
je vodik ili C1-C4 alkil izborno supstituiran s hidroksi; i
The apparatus of claim 1, wherein the entropy coder (130) scans the non-zero coefficients of each sub-block in a reverse direction from a last non-zero coefficient of each sub-block. 
Uređaj prema zahtjevu 1, naznačen time da entropijski koder (130) skenira ne-nulte koeficijente svakog pod-bloka u obrnutom smjeru od zadnjeg ne-nultog koeficijenta svakog pod-bloka koristeći mnoštvo obrazaca skeniranja.
The apparatus of claim 1, wherein the entropy coder (130) encodes positions of the non-zero coefficients and information for identifying the non-zero coefficients of each sub-block. 
Uređaj prema zahtjevu 1, naznačen time da entropijski koder (130) kodira položaje ne-nultih koeficijenata i informacije za identifikaciju ne-nultih koeficijenata svakog pod-bloka.
the structural units corresponding to Formula 1 constitute at least 85 wt.% based on the total weight of structural units of Formulae 1, 2, and 3 in the polymer calculated from the amounts of monomers used in the polymerization reaction, and the weight ratio of the structural unit corresponding to Formula 2 to the structural unit corresponding to Formula 3 is from 4:1 to 1:4, or 
strukturnih jedinica koje odgovaraju Formuli 1 sačinjava najmanje 85 tež.% bazirano na ukupnoj težini strukturnih jedinica s Formulama 1, 2, i 3 u polimeru računato s količinama monomera koje su korištene u polimerizacijskoj reakciji, te je težinski udio strukturne jedinice koja odgovara Formuli 2 prema strukturnoj jedinici koja odgovara Formuli 3 od 4:1 do 1:4, ili
the monomers corresponding to Formula 11 constitute at least 85 wt.% based on the total weight of monomers of Formulae 11, 22, and 33 in the polymerization mixture, and the weight ratio of the monomer corresponding to Formula 22 to the monomer corresponding to Formula 33 is from 4:1 to 1:4, or 
monomeri koji odgovaraju Formuli 11 sadrže najmanje 85 tež.% bazirano na ukupnoj težini monomera s Formulama 11, 22, i 33 u polimerizacijskoj mješavini i težinski udio monomera koji odgovaraju Formuli 22 prema monomerima koji odgovaraju Formuli 33 je od 4:1 do 1:4, ili
The pharmaceutical composition of claim 13 or 14 wherein the subject is a human and the human is being treated with an agent that causes potassium retention, the agent that causes potassium retention being an angiotensin-converting enzyme inhibitor (optionally captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazipril, fosinopril, or a combination thereof), an angiotensin receptor blocker (optionally candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, or a combination thereof), an aldosterone antagonist (optionally spironolactone, eplerenone, or a combination thereof). 
Farmaceutski pripravak prema bilo kojem od zahtjeva 12 do 14 naznačen time da subjekt je čovjek i čovjek se liječi sa sredstvom koje uzrokuje zadržavanje kalija, te sredstvo koje uzrokuje zadržavanje kalija je inhibitor angiotenzin-konvertirajućeg enzima (proizvoljno kaptopril, zofenopril, enalapril, ramipril, kinapril, perindopril, lizinopril, benazipril, fosinopril, ili njihova kombinacija), blokator receptora angiotenzina (proizvoljno kandesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, ili njihova kombinacija), antagonist aldosterona (proizvoljno spironolakton, eplerenon, ili njihova kombinacija).
wherein the monomers corresponding to Formula 11 constitute at least 85 wt.% based on the total weight of monomers of Formulae 11, 22, and 33 in the polymerization mixture, and the weight ratio of the monomer corresponding to Formula 22 to the monomer corresponding to Formula 33 is from 4:1 to 1:4, or 
strukturnih jedinica koje odgovaraju Formuli 1 sačinjava najmanje 85 tež.% bazirano na ukupnoj težini strukturnih jedinica s Formulama 1, 2, i 3 u polimeru računato s količinama monomera koje su korištene u polimerizacijskoj reakciji, te je težinski udio strukturne jedinice koja odgovara Formuli 2 prema strukturnoj jedinici koja odgovara Formuli 3 od 4:1 do 1:4, ili